STAT Plus: Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval
ALEX HOGAN/STAT
Despite concerns about the company's claims, many investors say they believe its experimental treatment could win FDA approval.
.png)
No hay comentarios:
Publicar un comentario